“Diamyd could have the world’s first diabetes vaccine out on the market in 2011,” says Elisabeth Lindner, President and CEO.
Diamyd Swedish doctor is a biopharmaceutical company focused on the development of pharmaceutical products for the treatment of autoimmune diabetes and its complications.
The most advanced project company is the GAD-based drug Diamyd ® for type 1 diabetes and for which Phase III trials are underway in both the US and Canada. and Europe.
Diamyd Medical has offices in Sweden and in the USA.